Adrenoleukodystrophy Analysis report covers 11 drugs currently in different phases of development. Adrenoleukodystrophy is a rare genetic disorder characterised by loss or damage of myelin sheath surrounding and insulating the nerve cells. The damage of the myelin sheath further leads to the progressive loss of the fuctioning of the adrenal glands. Symptoms of adrenoleukodystrophy are muscle spasms and pain, impaired vision, trouble balancing the body, deterioration of motor control, Adrenal insufficiency and lethargy and clumsiness. Diagnosis is done using blood tests, Skin biopsy and fibroblast cell culture and imaging tests.
The report provides ALD treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Applied Genetic Technologies Corporation, Magenta Therapeutics, Orpheris, Inc. and Vertex Pharmaceuticals Incorporated among others.
By Molecule Type
By Route of Administration